The University of Chicago (UChicago) Medical Center will be a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson's Phase 3 clinical research study, ENSEMBLE trial, to evaluate the safety and efficacy of the Janssen's investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S.
The Phase 3 randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the safety and efficacy of a single vaccine dose of the Janssen COVID-19 vaccine candidate versus placebo, in approximately 60,000 adults 18 years old and older, including significant representation from those that are older than 60.
The trial will include those both with and without co-morbidities associated with an increased risk for progression to severe COVID-19.
UChicago Medicine will enroll up to 2,000 adults ages 18 and older from within the Chicago community.
To support the recruitment process, Janssen has developed the ENSEMBLE Study website ENSEMBLEStudy.com where people interested in volunteering for the study can register.